SAN DIEGO–(BUSINESS WIRE)–Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced additional results from the older adult follow-on cohorts from its completed Phase 1 trial evaluating MF-300, a novel therapy in development for primary or age-related sarcopenia. In the older cohorts, the study met its primary safety endpoint, and the evaluated dose of MF-300 – corresponding to the maximum estimated phar
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
